Skip to main content

Table 2 Histology-driven approach in soft tissue sarcomas

From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new

Histology Cytotoxic compounds with selective activity Target-therapies with selective activities
Leiomyosarcoma Gemcitabine ± docetaxel, trabectedin, dacarbazine Pazopanib
Dedifferentiated liposarcoma High-dose ifosfamide, trabectedin, eribulin  
Myxoid liposarcoma Trabectedin, eribulin  
Synovial sarcoma Ifosfamide, trabectedin Pazopanib
Epithelioid sarcoma Gemcitabine Pazopanib
Angiosarcoma/intimal sarcoma Gemcitabine, paclitaxel Pazopanib, sorafenib
Alveolar soft part sarcoma   Pazopanib, sunitinib, cedinarib
Solitary fibrous tumour Dacarbazine Pazopanib, sunitinib
Clear cell sarcoma   Pazopanib, sunitinib
Extraskeletal myxoid chondrosarcoma   Pazopanib, sunitinib
Perivascular epithelioid cell tumor Gemcitabine m-TOR inhibitors
Epithelioid hemangioendothelioma   Pazopanib, m-TOR inhibitors, interferon
Inflammatory myofibroblastic tumour   Crizotinib
Undifferentiated pleomorphic sarcoma High-dose ifosfamide, gemcitabine  
Dermatofibrosarcoma protuberans   Imatinib, sorafenib, sunitinib
\